← FDA DRUG APPROVALS
FDA NDA · NDA022537
LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Sponsor: MACLEODS PHARMA
APPLICATION
NDA022537
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
LAMIVUDINE, NEVIRAPINE, AND STAVUDINENone (Tentative Approval)
LAMIVUDINE, NEVIRAPINE, AND STAVUDINE 150MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.